Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 28, 2016, Pages 7750-7755

  Liu, Yanlan ^a   Gunda, Viswanath ^b   Zhu, Xi ^a   Xu, Xiaoding ^a   Wu, Jun ^a   Askhatova, Diana ^a   Farokhzad, Omid C ^a   Parangi, Sareh ^b   Shi, Jinjun ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anaplastic thyroid cancer; Nanoparticle; NIR imaging; siRNA delivery; Theranostic

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; SMALL INTERFERING RNA; BRAF PROTEIN, MOUSE; NANOPARTICLE;

ADVANCED CANCER; ANAPLASTIC THYROID CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CELL DEDIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; FLUORESCENCE IMAGING; GENE SILENCING; HELA CELL LINE; HUMAN; HUMAN CELL; HYDROPHOBICITY; MOUSE; NANOTECHNOLOGY; NEAR INFRARED FLUORESCENCE NANOPLATFORM; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TREATMENT RESPONSE; TUMOR GROWTH; ANIMAL; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG SCREENING; GENETICS; NUDE MOUSE; PROCEDURES; SCID MOUSE; THERANOSTIC NANOMEDICINE; THYROID CARCINOMA; THYROID TUMOR;

ANIMALS; FEMALE; GENE SILENCING; HELA CELLS; HUMANS; MICE, NUDE; MICE, SCID; NANOPARTICLES; OPTICAL IMAGING; PROTO-ONCOGENE PROTEINS B-RAF; RNA, SMALL INTERFERING; THERANOSTIC NANOMEDICINE; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978136439     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1605841113     Document Type: Article

References (29)

1. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R (2013) Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol 2013:965212.
2. Smallridge RC, et al.; American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce (2012) American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22(11):1104-1139.
3. Xing M (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13(3):184-199.
4. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103(7):1330-1335.
5. Zuckerman JE, Davis ME (2015) Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov 14(12):843-856.
6. Maeda H, Nakamura H, Fang J (2013) The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65(1):71-79.
7. Tabernero J, et al. (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3(4):406-417.
8. Zuckerman JE, et al. (2014) Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci USA 111(31):11449-11454.
9. Prabhakar U, et al. (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73(8):2412-2417.
10. Miller MA, et al. (2015) Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Sci Transl Med 7(314):314ra183.
11. (99m)Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin. Cancer Chemother Pharmacol 74(1):211-215.
12. Choi KY, Liu G, Lee S, Chen X (2012) Theranostic nanoplatforms for simultaneous cancer imaging and therapy: Current approaches and future perspectives. Nanoscale 4(2):330-342.
13. Frangioni JV (2003) In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 7(5):626-634.
14. Wu C, Chiu DT (2013) Highly fluorescent semiconducting polymer dots for biology and medicine. Angew Chem Int Ed Engl 52(11):3086-3109.
15. Zhu X, et al. (2015) Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci USA 112(25):7779-7784.
16. Gilleron J, et al. (2013) Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 31(7):638-646.
17. Doherty GJ, McMahon HT (2009) Mechanisms of endocytosis. Annu Rev Biochem 78:857-902.
18. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov 8(2):129-138.
19. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46(12 Pt 1):6387-6392.
20. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5(4):505-515.
21. Kedmi R, Ben-Arie N, Peer D (2010) The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31(26):6867-6875.
22. Sanderson KM, Skinner D, Stein JP (2006) The prognostic and staging value of lymph node dissection in the treatment of invasive bladder cancer. Nat Clin Pract Urol 3(9):485-494.
23. Nucera C, et al. (2010) B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA 107(23):10649-10654.
24. Wan PT, et al.; Cancer Genome Project (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855-867.
25. Killion JJ, Radinsky R, Fidler IJ (1998-1999) Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 17(3):279-284.
26. Nucera C, et al. (2009) A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid 19(10):1077-1084.
27. Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJ, Frangioni JV (2013) Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol 10(9):507-518.
28. Pinto N, et al. (2014) Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer. J Oncol 2014(2014):936285.
29. Savvides P, et al. (2013) Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 23(5):600-604.